期刊文献+

药物洗脱球囊在冠状动脉粥样硬化性心脏病介入治疗中的应用进展 被引量:14

Progresses of drug eluting balloon in coronary artery disease intervention therapy
下载PDF
导出
摘要 药物洗脱球囊一经出现就备受关注,本文围绕药物洗脱球囊的发展历程、作用机制、临床效果等方面进行综述,文献来自近几年来发表的关于药物洗脱球囊的临床研究结果,涉及支架内再狭窄、小血管病变、分叉病变、弥漫性病变、急性心肌梗死等不同冠状动脉病变类型。结果显示,在支架内再狭窄、小血管病变、弥漫性病变的治疗领域中,药物洗脱球囊优于或不逊于药物支架,而在分叉病变和急性心肌梗死治疗领域中,药物洗脱球囊尚未达到与药物支架相当的临床疗效。药物洗脱球囊具有巨大的发展前景和空间,广泛应用于临床仍需要大量的研究证据。 Drug eluting balloon (DEB) has received much attention since it appeared. Recent researches about application of DEB involve stent restenosis, small vessel diseases, bifurcation lesion, diffuse lesion and infarct related vessels in acute myocardial infarction (AMI). It has been shown that DEB is superior or not inferior to drug eluting stent (DES) in treating stent restenosis, small vessel diseases and diffuse lesion, but not superior to DES in treating bifurcation lesion and infarct related vessels in AMI. In general, DEB shows a promising prospect, however more evidences are acquired for wide application. This article reviewed the mechanism, clinical effects and progresses of DEB.
出处 《中国医药》 2016年第2期290-292,共3页 China Medicine
关键词 冠状动脉疾病 药物洗脱球囊 介入治疗 Coronary artery disease Drug eluting balloon Coronary intervention treatment
  • 相关文献

参考文献19

  • 1Axe1 DI, Kunert W, Gggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery [ J ]. Circulation, 1997,96 ( 2 ) : 636-645. DOI: 10. 1161/01. CIR. 96.2. 636. 被引量:1
  • 2Kolachalmna VB, Pacetti SD, Franses JW, et al. Mechanisms of tis- sue uptake and retention in zotarolimus-coated balloon therapy [ J ]. Circulation, 2013,127 ( 20 ) : 2047-2055. DOI : 10. 1161/CIRCULA- TIONAHA. 113.1302051. 被引量:1
  • 3Kelsch B, Scheller B, Biedermann M, et al. Dose response to paclitaxel-coated balloon catheters in the porcine coronary overstretch and stent implantation model [ J ]. Invest Radiol, 2011,46(4) :255-263. DOI: 10. 1097/RLI. 0b013e31820577df. 被引量:1
  • 4Posa A, Nyolczas N, Hemetsberger R, et al. Optimization of drug-eluting balloon use for safety and efficacy: evaluation of the 2nd generation paclitaxel-eluting DIOR-balloon in porcine coro- nary arteries[ J]. Catheter Cardiovasc Interv, 2010,76 (3) : 395- 403. DOI: 10. 1002/ccd. 22468. 被引量:1
  • 5Loh JP, Barbash IM, Waksman R. The current status of drug-coated balloons in percutaneous coronary and peripheral interventions [ J ]. Eurolnterventiort, 2013,9 (8) :979-988. DOI: 10.4244/EIJV918A164. 被引量:1
  • 6Seheller B, Hehrlein C, Bocksch W, et al. Treatment of coronary in-stent restenosis with a paclitaxel-eoated balloon catheter [ J ]. N Engl J Med, 2006,355(20) :2113-2124. DOI: 10. 1056/NEJ- Moa061254. 被引量:1
  • 7Scheller B, Hehrlein C, Bocksch W, et al. Two year follow-up af- ter treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[ J]. Clin Res Cardiol, 2008,97 (10) :773-781. DOI: 10. 1007/s00392-008-0682-5. 被引量:1
  • 8Scheller B, Clever YP, Kelsch B, et al. Long-term follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter[J]. JACC Cardiovase Interv, 2012,5 (3):323- 330. DOI: 10. 1016/j. jcin. 2012.01. 008. 被引量:1
  • 9Byrne RA, Neumann FJ, Mehilli J, et al. Paclitaxel-eluting bal- loons, paclitaxel-eluting stents, and balloon angioplasty in pa- tients with restenosis after implantation of a drug-eluting stent ( ISAR-DESIRE 3) : a randomlsed, open-label trial[ J]. Lancet, 2013,381 (9865) :461-467. DOI: 10. 1016/S0140-6736 (12) 61964 -3. 被引量:1
  • 10Xu B, Gao R, Wang J, et al. A prospective, muhicenter, ran- domized trial of paclitaxel-coated balloon versus paclitaxel-eluting stent for the treatment of drug-eluting stent in-stent resterDsis: re- ! sults from the PEPCAD China ISR trial[J]. JACC Cardiovasc In- terv, 2014, 7 (2) : 204-211. DOI: 10. 1Q16/j. jcin. 2013.08.011. 被引量:1

同被引文献97

引证文献14

二级引证文献49

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部